Polyethylenimines for siRNA and miRNA delivery in vivo

Wiley Interdisciplinary Reviews: Nanomedicine and Nanobiotechnology

Volumn 5, Issue 5, 2013, Pages 484-501

  Höbel, Sabrina ^a   Aigner, Achim ^a  

^a UNIVERSITY OF LEIPZIG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

COVALENT COUPLINGS; NANOPARTICLE FORMULATION; NANOSCALE COMPLEXES; NATURALLY OCCURRING; PHARMACOKINETIC PROPERTIES; POSITIVELY CHARGED; SMALL INTERFERING RNA; THERAPEUTIC STRATEGY;

BIOCOMPATIBILITY; GENE EXPRESSION; GENE THERAPY;

RNA;

COMPLEMENTARY RNA; DOUBLE STRANDED RNA; HAMMERHEAD RIBOZYME; MICRORNA; MICRORNA 145; NANOPARTICLE; POLYETHYLENEIMINE DERIVATIVE; POLYINOSINIC POLYCYTIDYLIC ACID; RIBONUCLEASE III; RIBOZYME; SMALL INTERFERING RNA;

ANTIANGIOGENIC ACTIVITY; ANTIPROLIFERATIVE ACTIVITY; BIOCOMPATIBILITY; BIOLOGICAL ACTIVITY; CAENORHABDITIS ELEGANS; CELL VIABILITY; CELLULAR IMMUNITY; CHEMICAL MODIFICATION; COLON CANCER; COMPLEX FORMATION; DNA RNA HYBRIDIZATION; DNA TRANSFECTION; GENE DELIVERY SYSTEM; GENE EXPRESSION; GENE REPLACEMENT THERAPY; GENE SILENCING; GENE TARGETING; GENOMIC INSTABILITY; HUMAN; IN VITRO GENE TRANSFER; IN VITRO STUDY; IN VIVO STUDY; ISOTOPE LABELING; MELANOMA; MOLECULAR WEIGHT; NEOPLASM; NONHUMAN; NONVIRAL GENE DELIVERY SYSTEM; PHYSICAL CHEMISTRY; POSTTRANSCRIPTIONAL GENE SILENCING; PRIORITY JOURNAL; PROSTATE CARCINOMA; REVIEW; RING OPENING; RNA INTERFERENCE; RNA STRUCTURE; STATIC ELECTRICITY; STOMACH CANCER; STRUCTURE ACTIVITY RELATION; SURFACE PLASMON RESONANCE; UPREGULATION;

ANIMALS; BIOCOMPATIBLE MATERIALS; DRUG DELIVERY SYSTEMS; GENE TRANSFER TECHNIQUES; GENETIC THERAPY; HUMANS; LIGANDS; MICRORNAS; NANOPARTICLES; NEOPLASM TRANSPLANTATION; NEOPLASMS; NUCLEIC ACIDS; POLYETHYLENEIMINE; RNA INTERFERENCE; RNA, SMALL INTERFERING; TRANSFECTION;

EID: 84884820234     PISSN: 19395116     EISSN: 19390041     Source Type: Journal    
DOI: 10.1002/wnan.1228     Document Type: Review

References (82)

1. Napoli C, Lemieux C, Jorgensen R. Introduction of a chimeric chalcone synthase gene into petunia results in reversible co-suppression of homologous genes in trans. Plant Cell 1990, 2:279-289.
2. Fire A, Albertson D, Harrison SW, Moerman DG. Production of antisense RNA leads to effective and specific inhibition of gene expression in C. elegans muscle. Development 1991, 113:503-514.
3. Fire A, Xu S, Montgomery MK, Kostas SA, Driver SE, Mello CC. Potent and specific genetic interference by double-stranded RNA in Caenorhabditis elegans. Nature 1998, 391:806-811.
4. Hammond SM, Bernstein E, Beach D, Hannon GJ. An RNA-directed nuclease mediates post-transcriptional gene silencing in Drosophila cells. Nature 2000, 404:293-296.
5. Elbashir SM, Harborth J, Lendeckel W, Yalcin A, Weber K, Tuschl T. Duplexes of 21-nucleotide RNAs mediate RNA interference in cultured mammalian cells. Nature 2001, 411:494-498.
6. Hutvágner G, Zamore PD. A microRNA in a multiple-turnover RNAi enzyme complex. Science 2002, 297:2056-2060.
7. Aigner A. MicroRNAs (miRNAs) in cancer invasion and metastasis: therapeutic approaches based on metastasis-related miRNAs. J Mol Med (Berl) 2011, 89:445-457.
8. Pillai RS, Bhattacharyya SN, Filipowicz W. Repression of protein synthesis by miRNAs: how many mechanisms? Trends Cell Biol 2007, 17:118-126.
9. Zhuk DS, Gembitskii PA, Kargin VA. Advances in the chemistry of polyethylenimine (polyaziridine). Russ Chem Rev 1965, 34:517-527.
10. Kircheis R, Wightman L, Wagner E. Design and gene delivery activity of modified polyethylenimines. Adv Drug Deliv Rev 2001, 53:341-358.
11. Jäger M, Schubert S, Ochrimenko S, Fischer D, Schubert US. Branched and linear poly(ethylene imine)-based conjugates: synthetic modification, characterization, and application. Chem Soc Rev 2012, 41:4755-4767.
12. Brissault B, Kichler A, Guis C, Leborgne C, Danos O, Cheradame H. Synthesis of linear polyethylenimine derivatives for DNA transfection. Bioconjug Chem 2003, 14:581-587.
13. Boussif O, Lezoualc'h F, Zanta MA, Mergny MD, Scherman D, Demeneix B, Behr JP. A versatile vector for gene and oligonucleotide transfer into cells in culture and in vivo: polyethylenimine. Proc Natl Acad Sci U S A 1995, 92:7297-7301.
14. Behr J. The proton sponge: a trick to enter cells the viruses did not exploit. Chimia 1997, 2:34-36.
15. Mintzer MA, Simanek EE. Nonviral vectors for gene delivery. Chem Rev 2009, 109:259-302.
16. Breunig M, Lungwitz U, Liebl R, Goepferich A. Breaking up the correlation between efficacy and toxicity for nonviral gene delivery. Proc Natl Acad Sci U S A 2007, 104:14454-14459.
17. Fischer D, Bieber T, Li Y, Elsässer HP, Kissel T. A novel non-viral vector for DNA delivery based on low molecular weight, branched polyethylenimine: effect of molecular weight on transfection efficiency and cytotoxicity. Pharm Res 1999, 16:1273-1279.
18. Werth S, Urban-Klein B, Dai L, Höbel S, Grzelinski M, Bakowsky U, Czubayko F, Aigner A. A low molecular weight fraction of polyethylenimine (PEI) displays increased transfection efficiency of DNA and siRNA in fresh or lyophilized complexes. J Control Release 2006, 112:257-270.
19. Stephenson ML, Zamecnik PC. Inhibition of Rous sarcoma viral RNA translation by a specific oligodeoxyribonucleotide. Proc Natl Acad Sci U S A 1978, 75:285-288.
20. Zamecnik PC, Stephenson ML. Inhibition of Rous sarcoma virus replication and cell transformation by a specific oligodeoxynucleotide. Proc Natl Acad Sci U S A 1978, 75:280-284.
21. Abdallah B, Hassan A, Benoist C, Goula D, Behr JP, Demeneix BA. A powerful nonviral vector for in vivo gene transfer into the adult mammalian brain: polyethylenimine. Hum Gene Ther 1996, 7:1947-1954.
22. Boletta A, Benigni A, Lutz J, Remuzzi G, Soria MR, Monaco L. Nonviral gene delivery to the rat kidney with polyethylenimine. Hum Gene Ther 1997, 8:1243-1251.
23. Goula D, Benoist C, Mantero S, Merlo G, Levi G, Demeneix BA. Polyethylenimine-based intravenous delivery of transgenes to mouse lung. Gene Ther 1998, 5:1291-1295.
24. Basarkar A, Singh J. Nanoparticulate systems for polynucleotide delivery. Int J Nanomedicine 2007, 2:353-360.
25. Chollet P, Favrot MC, Hurbin A, Coll JL. Side-effects of a systemic injection of linear polyethylenimine-DNA complexes. J Gene Med 2002, 4:84-91.
26. Beyerle A, Braun A, Merkel O, Koch F, Kissel T, Stoeger T. Comparative in vivo study of poly(ethylene imine)/siRNA complexes for pulmonary delivery in mice. J Control Release 2011, 151:51-56.
27. Thomas M, Lu JJ, Ge Q, Zhang C, Chen J, Klibanov AM. Full deacylation of polyethylenimine dramatically boosts its gene delivery efficiency and specificity to mouse lung. Proc Natl Acad Sci U S A 2005, 102:5679-5684.
28. Höbel S, Appeldoorn CCM, Gaillard PJ, Aigner A. Targeted CRM197-PEG-PEI/siRNA complexes for therapeutic RNAi in glioblastoma. Pharmaceuticals 2011, 4:1591-1606.
29. Malek A, Merkel O, Fink L, Czubayko F, Kissel T, Aigner A. In vivo pharmacokinetics, tissue distribution and underlying mechanisms of various PEI(-PEG)/siRNA complexes. Toxicol Appl Pharmacol 2009, 236:97-108.
30. Merkel OM, Beyerle A, Librizzi D, Pfestroff A, Behr TM, Sproat B, Barth PJ, Kissel T. Nonviral siRNA Delivery to the lung: investigation of PEG-PEI polyplexes and their in vivo performance. Mol Pharm 2009, 6:1246-1260.
31. Höbel S, Loos A, Appelhans D, Schwarz S, Seidel J, Voit B, Aigner A. Maltose- and maltotriose-modified, hyperbranched poly(ethylene imine)s (OM-PEIs): Physicochemical and biological properties of DNA and siRNA complexes. J Control Release 2011, 149:146-158.
32. Schiffelers RM, Ansari A, Xu J, Zhou Q, Tang Q, Storm G, Molema G, Lu PY, Scaria PV, Woodle MC. Cancer siRNA therapy by tumor selective delivery with ligand-targeted sterically stabilized nanoparticle. Nucleic Acids Res 2004, 32:e149.
33. Lu ZX, Liu LT, Qi XR. Development of small interfering RNA delivery system using PEI-PEG-APRPG polymer for antiangiogenic vascular endothelial growth factor tumor-targeted therapy. Int J Nanomedicine 2011, 6:1661-1673.
34. Hwang do W, Son S, Jang J, Youn H, Lee S, Lee D, Lee YS, Jeong JM, Kim WJ, Lee DS. A brain-targeted rabies virus glycoprotein-disulfide linked PEI nanocarrier for delivery of neurogenic microRNA. Biomaterials 2011, 32:4968-4975.
35. Jang YL, Yun UJ, Lee MS, Kim MG, Son S, Lee K, Chae SY, Lim DW, Kim HT, Kim SH, et al. Cell-penetrating peptide mimicking polymer-based combined delivery of paclitaxel and siRNA for enhanced tumor growth suppression. Int J Pharm 2012, 434:488-493.
36. Jiang G, Park K, Kim J, Kim KS, Hahn SK. Target specific intracellular delivery of siRNA/PEI-HA complex by receptor mediated endocytosis. Mol Pharm 2009, 6:727-737.
37. Kang JH, Tachibana Y, Kamata W, Mahara A, Harada-Shiba M, Yamaoka T. Liver-targeted siRNA delivery by polyethylenimine (PEI)-pullulan carrier. Bioorg Med Chem 2010, 18:3946-3950.
38. Schaffert D, Kiss M, Rödl W, Shir A, Levitzki A, Ogris M, Wagner E. Poly(I:C)-mediated tumor growth suppression in EGF-receptor overexpressing tumors using EGF-polyethylene glycol-linear polyethylenimine as carrier. Pharm Res 2011, 28:731-741.
39. Shen M, Gong F, Pang P, Zhu K, Meng X, Wu C, Wang J, Shan H, Shuai X. An MRI-visible non-viral vector for targeted Bcl-2 siRNA delivery to neuroblastoma. Int J Nanomedicine 2012, 7:3319-3332.
40. Xue HY, Wong HL. Solid lipid-PEI hybrid nanocarrier: an integrated approach to provide extended, targeted, and safer siRNA therapy of prostate cancer in an all-in-one manner. ACS Nano 2011, 5:7034-7047.
41. Alshamsan A, Hamdy S, Samuel J, El-Kadi AO, Lavasanifar A, Uludaǧ H. The induction of tumor apoptosis in B16 melanoma following STAT3 siRNA delivery with a lipid-substituted polyethylenimine. Biomaterials 2010, 31:1420-1428.
42. Laroui H, Theiss AL, Yan Y, Dalmasso G, Nguyen HT, Sitaraman SV, Merlin D. Functional TNFα gene silencing mediated by polyethyleneimine/TNFα siRNA nanocomplexes in inflamed colon. Biomaterials 2011, 32:1218-1228.
43. Huh MS, Lee SY, Park S, Lee S, Chung H, Lee S, Choi Y, Oh YK, Park JH, Jeong SY, et al. Tumor-homing glycol chitosan/polyethylenimine nanoparticles for the systemic delivery of siRNA in tumor-bearing mice. J Control Release 2010, 144:134-143.
44. Creusat G, Thomann JS, Maglott A, Pons B, Dontenwill M, Guérin E, Frisch B, Zuber G. Pyridylthiourea-grafted polyethylenimine offers an effective assistance to siRNA-mediated gene silencing in vitro and in vivo. J Control Release 2012, 157:418-426.
45. Zheng M, Librizzi D, Ki{dotless}li{dotless}ç A, Liu Y, Renz H, Merkel OM, Kissel T. Enhancing in vivo circulation and siRNA delivery with biodegradable polyethylenimine-graft-polycaprolactone-block-poly(ethylene glycol) copolymers. Biomaterials 2012, 33:6551-6558.
46. Kim WJ, Chang CW, Lee M, Kim SW. Efficient siRNA delivery using water soluble lipopolymer for anti-angiogenic gene therapy. J Control Release 2007, 118:357-363.
47. Kim SHW, Jeong JH, Lee SH, Park TG. Local and systemic delivery of VEGF siRNA using polyelectrolyte complex micelles for effective treatment of cancer. J Control Release 2008, 129:107-116.
48. Kim YM, Park MR, Song SC. Injectable polyplex hydrogel for localized and long-term delivery of siRNA. ACS Nano 2012, 6:5757-5766.
49. Mountziaris PM, Tzouanas SN, Sing DC, Kramer PR, Kasper FK, Mikos AG. Intra-articular controlled release of anti-inflammatory siRNA with biodegradable polymer microparticles ameliorates temporomandibular joint inflammation. Acta Biomater 2012, 8:3552-3560.
50. Murata N, Takashima Y, Toyoshima K, Yamamoto M, Okada H. Anti-tumor effects of anti-VEGF siRNA encapsulated with PLGA microspheres in mice. J Control Release 2008, 126:246-254.
51. Mao S, Neu M, Germershaus O, Merkel O, Sitterberg J, Bakowsky U, Kissel T. Influence of polyethylene glycol chain length on the physicochemical and biological properties of poly(ethylene imine)-graft-poly(ethylene glycol) block copolymer/SiRNA polyplexes. Bioconjug Chem 2006, 17:1209-1218.
52. Malek A, Czubayko F, Aigner A. PEG grafting of polyethylenimine (PEI) exerts different effects on DNA transfection and siRNA-induced gene targeting efficacy. J Drug Target 2008, 16:124-139.
53. Dash PR, Read ML, Barrett LB, Wolfert MA, Seymour LW. Factors affecting blood clearance and in vivo distribution of polyelectrolyte complexes for gene delivery. Gene Ther 1999, 6:643-650.
54. Harris JM, Martin NE, Modi M. Pegylation: a novel process for modifying pharmacokinetics. Clin Pharmacokinet 2001, 40:539-551.
55. Shir A, Ogris M, Roedl W, Wagner E, Levitzki A. EGFR-homing dsRNA activates cancer-targeted immune response and eliminates disseminated EGFR-overexpressing tumors in mice. Clin Cancer Res 2011, 17:1033-1043.
56. Cubillos-Ruiz JR, Baird JR, Tesone AJ, Rutkowski MR, Scarlett UK, Camposeco-Jacobs AL, Anadon-Arnillas J, Harwood NM, Korc M, Fiering SN, et al. Reprogramming tumor-associated dendritic cells in vivo using miRNA mimetics triggers protective immunity against ovarian cancer. Cancer Res 2012, 72:1683-1693.
57. Aigner A, Fischer D, Merdan T, Brus C, Kissel T, Czubayko F. Delivery of unmodified bioactive ribozymes by an RNA-stabilizing polyethylenimine (LMW-PEI) efficiently down-regulates gene expression. Gene Ther 2002, 9:1700-1707.
58. Ge Q, Filip L, Bai A, Nguyen T, Eisen HN, Chen J. Inhibition of influenza virus production in virus-infected mice by RNA interference. Proc Natl Acad Sci U S A 2004, 101:8676-8681.
59. Urban-Klein B, Werth S, Abuharbeid S, Czubayko F, Aigner A. RNAi-mediated gene-targeting through systemic application of polyethylenimine (PEI)-complexed siRNA in vivo. Gene Ther 2005, 12:461-466.
60. Geisbert TW, Hensley LE, Kagan E, Yu EZ, Geisbert JB, Daddario-DiCaprio K, Fritz EA, Jahrling PB, McClintock K, Phelps JR, et al. Postexposure protection of guinea pigs against a lethal ebola virus challenge is conferred by RNA interference. J Infec Dis 2006, 193:1650-1657.
61. Grzelinski M, Urban-Klein B, Martens T, Lamszus K, Bakowsky U, Höbel S, Czubayko F, Aigner A. RNA interference-mediated gene silencing of pleiotrophin through polyethylenimine-complexed small interfering RNAs in vivo exerts antitumoral effects in glioblastoma xenografts. Hum Gene Ther 2006, 17:751-766.
62. de Wolf HK, Snel CJ, Verbaan FJ, Schiffelers RM, Hennink WE, Storm G. Effect of cationic carriers on the pharmacokinetics and tumor localization of nucleic acids after intravenous administration. Int J Pharm 2007, 331:167-175.
63. Segura T, Schmokel H, Hubbell JA. RNA interference targeting hypoxia inducible factor 1α reduces post-operative adhesions in rats. J Surg Res 2007, 141:162-170.
64. Lively TN, Kossen K, Balhorn A, Koya T, Zinnen S, Takeda K, Lucas JJ, Polisky B, Richards IM, Gelfand EW. Effect of chemically modified IL-13 short interfering RNA on development of airway hyperresponsiveness in mice. J Allergy Clin Immunol 2008, 121:88-94.
65. Wang S, Xu J, Song P, Wu Y, Zhang J, Chul Choi H, Zou MH. Acute inhibition of guanosine triphosphate cyclohydrolase 1 uncouples endothelial nitric oxide synthase and elevates blood pressure. Hypertension 2008, 52:484-490.
66. Yang YD, Cho H, Koo JY, Tak MH, Cho Y, Shim WS, Park SP, Lee J, Lee B, Kim BM, et al. TMEM16A confers receptor-activated calcium-dependent chloride conductance. Nature 2008, 455:1210-1215.
67. Höbel S, Koburger I, John M, Czubayko F, Hadwiger P, Vornlocher HP, Aigner A. Polyethylenimine/small interfering RNA-mediated knockdown of vascular endothelial growth factor in vivo exerts anti-tumor effects synergistically with Bevacizumab. J Gene Med 2010, 12:287-300.
68. Kiguchi N, Maeda T, Kobayashi Y, Fukazawa Y, Kishioka S. Macrophage inflammatory protein-1α mediates the development of neuropathic pain following peripheral nerve injury through interleukin-1β up-regulation. Pain 2010, 149:305-315.
69. Kim MY, Seo EJ, Lee DH, Kim EJ, Kim HS, Cho HY, Chung EY, Lee SH, Baik EJ, Moon CH, et al. Gadd45β is a novel mediator of cardiomyocyte apoptosis induced by ischaemia/hypoxia. Cardiovasc Res 2010, 87:119-126.
70. Lan LS, Ping YJ, Na WL, Miao J, Cheng QQ, Ni MZ, Lei L, Fang LC, Guang RC, Jin Z, et al. Down-regulation of Toll-like receptor 4 gene expression by short interfering RNA attenuates bone cancer pain in a rat model. Mol Pain 2010, 6:2.
71. Xu D, Takeshita F, Hino Y, Fukunaga S, Kudo Y, Tamaki A, Matsunaga J, Takahashi RU, Takata T, Shimamoto A, et al. miR-22 represses cancer progression by inducing cellular senescence. J Cell Biol 2011, 193:409-424.
72. Kaestner P, Aigner A, Bastians H. Therapeutic targeting of the mitotic spindle checkpoint through nanoparticle-mediated siRNA delivery inhibits tumor growth in vivo. Cancer Lett 2011, 304:128-136.
73. Knight M, Miller A, Liu Y, Scaria P, Woodle M, Ittiprasert W. Polyethyleneimine (PEI) mediated siRNA gene silencing in the Schistosoma mansoni snail host Biomphalaria glabrata. PLoS Negl Trop Dis 2011, 5:e1212.
74. Ibrahim AF, Weirauch U, Thomas M, Grünweller A, Hartmann RK, Aigner A. MicroRNA replacement therapy for miR-145 and miR-33a is efficacious in a model of colon carcinoma. Cancer Res 2011, 71:5214-5224.
75. Hendruschk S, Wiedemuth R, Aigner A, Töpfer K, Cartellieri M, Martin D, Kirsch M, Ikonomidou C, Schackert G, Temme A. RNA interference targeting survivin exerts antitumoral effects in vitro and in established glioma xenografts in vivo. Neuro Oncol 2011, 13:1074-1089.
76. Lu J, Tao Y, Yang X, Tu W, Chen H, Xiong J, Hu C. Water-soluble lipopolymer delivery of N-methyl-D-aspartic acid receptor 2B siRNA relieves chronic neuropathic pain in rats. Neural Regen Res 2011, 6:2279-2283.
77. Xia W, Lin C. Bioreducible polymer-delivered siRNA targeting human telomerase reverse transcriptase for human cancer gene therapy. Ther Deliv 2012, 3:439-442.
78. Mostafa Anower AK, Shim JA, Choi B, Sohn S. Pretreatment with interleukin-6 small interfering RNA can improve the survival rate of polymicrobial cecal ligation and puncture mice by down regulating interleukin-6 production. Eur J Pharmacol 2012, 688:76-83.
79. Cilenti L, Balakrishnan MP, Wang XL, Ambivero C, Sterlicchi M, del Monte F, Ma XL, Zervos AS. Regulation of Abro1/KIAA0157 during myocardial infarction and cell death reveals a novel cardioprotective mechanism for Lys63-specific deubiquitination. J Mol Cell Cardiol 2011, 50:652-661.
80. Chen H, Chen L, Sun L, Zhen H, Li X, Zhang Q. A small interfering RNA targeting the KLF6 splice variant, KLF6-SV1, as gene therapy for gastric cancer. Gastric Cancer 2011, 14:339-352.
81. Thomas M, Lange-Grünweller K, Weirauch U, Gutsch D, Aigner A, Grünweller A, Hartmann RK. The proto-oncogene Pim-1 is a target of miR-33a. Oncogene 2012, 31:918-928.
82. Aigner A. Delivery systems for the direct application of siRNAs to induce RNA interference (RNAi) in vivo. J Biomed Biotechnol 2006, 2006:71659.